NRG Therapeutics said that it has appointed three senior executives as it advances its lead drug candidate, NRG5051, toward first-in-human clinical trials. The company said that the new roles include VP of Translational Biology, Director of Clinical Operations and Director of Project Management.
According to the company, NRG5051 is an orally-available, brain-penetrant small molecule inhibitor of the mitochondrial permeability transition pore (mPTP), a novel target in neurodegenerative disease.
The company said that these appointments accompany recent series B financing of £50 million led by SV Health Investors’ Dementia Discovery Fund, which will fund its development program through Phase 2 clinical proof-of-concept in indications including amyotrophic lateral sclerosis (ALS) and Parkinson’s disease.
NRG Therapeutics said that it plans to commence first-in-human studies of NRG5051 in early 2026. The leadership additions expand the company’s in-house team, which remains based in the UK while leveraging an outsourcing model for R&D and operations.
